<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927067</url>
  </required_header>
  <id_info>
    <org_study_id>SHP620-302</org_study_id>
    <secondary_id>2015-004726-34</secondary_id>
    <nct_id>NCT02927067</nct_id>
  </id_info>
  <brief_title>Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of maribavir to
      valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic
      hematopoietic stem cell transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EFFICACY OF MARIBAVIR COMPARED TO VALGANCICLOVIR IN CONFMIRMED CMV VIREMIA CLEARANCE AT THE END OF STUDY WEEK 8, REGARDLESS OF WHETHER STUDY ASSIGNED TREATMENT WAS COMPLETED</measure>
    <time_frame>Week 8</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. &lt;137 International Units Per Millilitre [IU/mL]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. The patient must have received exclusively study-assigned treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF CONFIRMED CMV VIREMIA CLEARANCE ACHIEVED AT THE END OF STUDY WEEK 8 THROUGH STUDY WEEK 16.</measure>
    <time_frame>Week 8 through Week 16</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay. The patient must have received exclusively study-assigned treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACHIEVEMENT CONFIRMED CMV VIREMIA CLEARANCE AFTER 8 WEEKS OF RECEIVING STUDY-ASSIGNED TREATMENT</measure>
    <time_frame>Week 8</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF CONFIRMED CMV VIREMIA CLEARANCE, ACHIEVED AFTER COMPLETION OF 8 WEEKS OF STUDY-ASSIGNED TREATMENT THROUGH STUDY WEEKS 12, 16 AND 20</measure>
    <time_frame>Week 8, Week 12, Week 16 and Week 20</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF CONFIRMED CMV VIREMIA CLEARANCE ACHIEVED AT THE END OF STUDY WEEK 8 WEEK THROUGH STUDY WEEKS 12, 16 AND 20, REGARDLESS OF WHETHER STUDY ASSIGNED TREATMENT WAS COMPLETED.</measure>
    <time_frame>Week 8, Week 12 and Week 20</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RECURRENCE OF CONFIRMED CMV VIREMIA IN THE 2 STUDY TREATMENT ARMS WHEN SUBJECTS ARE ON TREATMENT AND OFF TREATMENT</measure>
    <time_frame>Baseline up to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration greater than or equal to (&gt;=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable (&lt;LLOQ) for at least 5 days in 2 consecutive samples during the first 8 weeks of the study, during the 12 weeks of the followup study phase, and at any time during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 or 4 Neutropenia</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Grade 3 and grade 4 neutropenia are defined as absolute neutophil count (ANC) &lt;1000/ cubiv millimeter (mm^3) and ANC &lt;500/mm^3 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Maribavir Compared to Valganciclovir</measure>
    <time_frame>Baseline up to Week 20</time_frame>
    <description>Adverse events (AEs), vital signs, physical examinations and clinical laboratory tests will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of maribavir</measure>
    <time_frame>Week 8</time_frame>
    <description>AUC, Cmax, and Cmin will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Cytomegalovirus (CMV)</condition>
  <arm_group>
    <arm_group_label>Maribavir/ Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg tablets administered orally at 400mg (2 tablets) twice daily with food and placebo tablets (2 tablets) with the same appearance and route of administration as valganciclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valganciclovir/ Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>450mg tablets administered orally at 900mg (2 tablets) twice daily with food and placebo tablets (2 tablets) with the same appearance and route of administration as maribavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maribavir</intervention_name>
    <description>200mg tablets</description>
    <arm_group_label>Maribavir/ Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>450mg tablets</description>
    <arm_group_label>Valganciclovir/ Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets with the same appearance and route of administration as either maribavir or valganciclovir</description>
    <arm_group_label>Maribavir/ Placebo</arm_group_label>
    <arm_group_label>Valganciclovir/ Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be able to provide written, personally signed, and dated informed consent to
             participate in the study before completing any study-related procedures. As
             applicable, a parent/both parents or legally authorized representative (LAR) must
             provide signature of informed consent and there must be documentation of assent by the
             subject before completing any study-related procedures.

          2. Be greater than or equal to (&gt;=) 16 years of age at the time of consent.

          3. Be a recipient of hematopoietic stem cell transplant.

          4. Have a documented asymptomatic CMV infection, with a screening value of CMV DNA &gt;=2730
             IU/mL to less than or equal to (&lt;=) 273000 IU/mL in whole blood or &gt;=910 IU/mL to
             &lt;=91000 IU/mL in plasma in 2 consecutive assessments, separated by at least 1 day, as
             determined by local or central specialty laboratory quantitative polymerase chain
             reaction (qPCR) or comparable quantitative CMV DNA results. Both samples should be
             taken within 14 days prior to randomization with second sample obtained within 5 days
             prior to randomization. Same laboratory and same sample type (whole blood or plasma)
             should be used for these assessments. Asymptomatic CMV infection is defined as an
             infection that does not present with tissue invasive CMV disease, as assessed by the
             investigator.

          5. Have the current CMV infection as the first episode of CMV viremia after HSCT, either
             primary or reactivation.

          6. Per investigator's judgment, be eligible for treatment with valganciclovir.

          7. Have all of the following results as part of screening laboratory assessments (results
             from either the central laboratory or a local laboratory can be used for
             qualification):

               1. Absolute neutrophil count &gt;=1000/mm^3 [1.0 x 10^9/ liter (L)]

               2. Platelet count &gt;=25,000/mm^3 [25 x 10^9/L]

               3. Hemoglobin &gt;=8 gram per deciliter (g/dL).

               4. Estimated creatinine clearance &gt;=60mL/min/1.73 square meter (m^2)

          8. Have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test at
             screening, if a female of child bearing potential. Urine pregnancy tests may be done
             per institutional requirements; however they are not sufficient for eligibility
             determination. Sexually active females of child bearing potential must agree to comply
             with any applicable contraceptive requirements of the protocol. If male, must agree to
             use an acceptable method of birth control, as defined in the protocol, during the
             study treatment administration period and for 90 days afterward the last dose of study
             treatment.

          9. Be able to swallow tablets.

         10. Have life expectancy of &gt;=8 weeks.

         11. Weigh &gt;=40 kg.

         12. Be willing and have an understanding and ability to fully comply with study procedures
             and restrictions defined in the protocol.

        Exclusion Criteria:

          1. Have CMV tissue invasive disease as assessed by the investigator at the time of
             screening and randomization at Visit 2/Day 0.

          2. Have a CMV infection that is known to be genotypically resistant to ganciclovir,
             valganciclovir, foscarnet, or cidofovir based on documented evidence.

          3. Be presenting with recurrent CMV infection (defined as a new detection of CMV
             infection in a subject who had at least one previously documented episode of CMV
             infection posttransplant, and who has had at least 2 weeks of undetectable CMV DNA
             between the episodes (during active surveillance, based on same local laboratory and
             same sample type). The subject must also have been off any anti-CMV treatment between
             the current and prior infection. Otherwise, the current infection may be considered
             continuation of the prior infection.

          4. Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for
             conditions other than CMV when study treatment is initiated (example: herpes simplex
             virus [HSV] coinfection requiring use of any of these agents after the randomization)
             or would need a co-administration with maribavir for CMV infection.

          5. Be receiving leflunomide, or artesunate when study treatment is initiated. Note:
             Subjects who may be receiving leflunomide must discontinue the use at least 14 days
             prior to randomization at Visit 2/Day 0 and the first dose of study treatment.
             Subjects receiving artesunate must discontinue the use prior to the first dose of
             study treatment.

          6. Be on treatment with anti-CMV agents (ganciclovir, valganciclovir, foscarnet or
             cidofovir) for the current CMV infection for longer than 72 hours.

             Note: A subject who is receiving these anti-CMV agents must discontinue their use
             before the first dose of study treatment. A subjects who may be receiving cidofovir
             must discontinue this antiviral at least 14 days prior to randomization at Visit 2/Day
             0 and the first dose of study treatment.

             Note: Subjects who were administered these anti-CMV agents for prophylaxis, should
             have these treatments completed at least 2 weeks prior to the study entry or start of
             the treatment for current infection, whichever comes first and have undetectable CMV
             DNA (based on local laboratory) for at least two weeks between the completion of this
             treatment and onset of the current infection.

          7. Have known hypersensitivity to the active substance or to an excipient of the study
             treatments.

          8. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24
             hours prior to the first dose of study treatment that would preclude administration of
             oral medication.

          9. Require mechanical ventilation or vasopressors for hemodynamic support at the time of
             randomization.

         10. Be female and pregnant or nursing.

         11. Have previously completed, discontinued, or have been withdrawn from this study.

         12. Have received any investigational agent with known anti-CMV activity within 30 days
             before initiation of study treatment or CMV vaccine at any time.

         13. Have received any unapproved agent or device within 30 days before initiation of study
             treatment.

         14. Have any clinically significant medical or surgical condition that, in the
             investigator's opinion, could interfere with interpretation of study results,
             contraindicate the administration of the assigned study treatment, or compromise the
             safety or well-being of the subject.

         15. Have previously received maribavir.

         16. Have serum aspartate aminotransferase (AST) &gt;5 times upper limit of normal (ULN) at
             screening, or serum alanine aminotransferase (ALT) &gt;5 times ULN at screening, or total
             bilirubin &gt;=3.0 x ULN at screening (except for documented Gilbert's syndrome), as
             analyzed by local or central lab.

         17. Have known (previously documented) positive results for human immunodeficiency virus
             (HIV).

         18. Have active malignancy with the exception of nonmelanoma skin cancer, as determined by
             the investigator. Subjects who experience relapse or progression of their underlying
             malignancy (for which HSCT was performed), as determined by the investigator, are not
             to be enrolled.

         19. Be undergoing treatment for acute or chronic hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>866-842-5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Baddley, MD, MSPH</last_name>
      <phone>205-934-5191</phone>
      <email>jbaddley@uab.edu</email>
    </contact>
    <investigator>
      <last_name>John Baddley, MD, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Winston, MD</last_name>
      <phone>310-825-6264</phone>
      <email>dwinston@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Drew Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Brown, MD</last_name>
      <phone>650-868-8073</phone>
      <email>wesbrown@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Janice Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Nash, MD</last_name>
      <phone>720-754-4800</phone>
      <email>richard.nash@healthonecares.com</email>
    </contact>
    <investigator>
      <last_name>Richard Nash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricar Malinis, MD</last_name>
      <phone>203-785-3561</phone>
      <email>maricar.malinis@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Maricar Malinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Lyon, MD</last_name>
      <phone>404-712-2051</phone>
      <email>gmlyon@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Theusch</last_name>
      <phone>773-702-1665</phone>
      <email>jtheusch@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Mullane, DO, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Yared, MD</last_name>
      <phone>410-328-0386</phone>
      <email>jyared@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Yared, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Woessner</last_name>
      <phone>410-614-6702</phone>
      <email>twoessn1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Avery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital/Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Marty, MD</last_name>
      <phone>617-732-8881</phone>
      <email>fmarty@partners.org</email>
    </contact>
    <investigator>
      <last_name>Francisco Marty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Gibson, MD</last_name>
      <phone>508-856-1978</phone>
      <email>laura.gibson@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Williams</last_name>
      <phone>313-916-5401</phone>
      <email>kwilli35@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>George Alangaden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo-Anne Young, MD</last_name>
      <phone>612-625-8642</phone>
      <email>vanbu004@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>59905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymund Razonable, MD</last_name>
      <phone>507-284-3747</phone>
      <email>razonable.raymund@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Raymund Razonable, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Rowley, MD</last_name>
      <phone>551-996-5234</phone>
      <email>scott.rowley@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Scott Rowley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joan and sandford I. Weill Medical College of Cornell University Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsiporah Shore, MD</last_name>
      <phone>212-746-2646</phone>
      <email>tbs2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Tsiporah Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genovefa Papnicolaou, MD</last_name>
      <phone>212-639-8361</phone>
      <email>papanicg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Genovefa Papanicolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ran Reshef, MD, MSc</last_name>
      <phone>212-342-0530</phone>
      <email>rr336@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ran Reshef, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Blumberg, MD</last_name>
      <phone>215-662-7066</phone>
      <email>blumbere@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Blumberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriStar Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Bachier, MD</last_name>
      <phone>210-575-6904</phone>
      <email>carlos.bachier@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Bachier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.David's South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aravind Ramakrishnan, MD</last_name>
      <phone>201-575-6904</phone>
      <email>aravind.ramakrishnan@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Aravind Ramakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Chemaly, MD</last_name>
      <phone>713-792-5381</phone>
      <email>rfchemaly@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Roy Chemaly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Shaughnessy, MD</last_name>
      <phone>210-575-8500</phone>
      <email>paul.shaughnessy@mhshealth.com</email>
    </contact>
    <investigator>
      <last_name>Paul Shaughnessy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System - NAVREF</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Chauncey, MD</last_name>
      <phone>206-764-2969</phone>
      <email>tchaunce@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Chauncey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parameswaran Hari, MD</last_name>
      <phone>414-805-4600</phone>
      <email>phari@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Parameswaran Hari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Blyth, MBBS</last_name>
      <phone>+61298457073</phone>
      <email>emily.blyth@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Emily Blyth, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Sasadeusz, MD, PhD</last_name>
      <phone>+61393429407</phone>
      <email>joe.sasadeusz@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Joe Sasadeusz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Gadisseur, MD, PhD</last_name>
      <phone>+3238213250</phone>
      <email>alain.gadisseur@uza.be</email>
    </contact>
    <investigator>
      <last_name>Alain Gadisseur, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickaël Aoun, MD</last_name>
      <phone>+3225413706</phone>
      <email>mickael.aoun@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Mickaël Aoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Poiré, MD</last_name>
      <phone>+3227641809</phone>
      <email>xavier.poire@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Xavier Poiré, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Kerre, MD</last_name>
      <phone>+3293326654</phone>
      <email>tessa.kerre@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Tessa Kerre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD</last_name>
      <phone>+3216346880</phone>
      <email>johan.maertens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Selleslag, MD</last_name>
      <phone>+3250453061</phone>
      <email>dominik.selleslag@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyne Willems, MD</last_name>
      <phone>+3243667201</phone>
      <email>e.willems@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Evelyne Willems, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa Wright, MD</last_name>
      <phone>(604) 875-4588</phone>
      <email>alissa.wright@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Alissa Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Couban, MD</last_name>
      <phone>(902) 473-4642</phone>
      <email>stephen.couban@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Couban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shariq Haider, MD</last_name>
      <phone>(905) 521-2100</phone>
      <phone_ext>42199</phone_ext>
      <email>haider@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Shariq Haider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radovan Vrhovac, MD</last_name>
      <phone>+38598230220</phone>
      <email>rvrhovac@mef.hr</email>
    </contact>
    <investigator>
      <last_name>Radovan Vrhovac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Lioure, MD</last_name>
      <phone>+33388116728</phone>
      <email>bruno.lioure@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Lioure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Clement, MD</last_name>
      <phone>+33557656511</phone>
      <email>laurence.clement@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Clement, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>GRENOBLE Cedex 9</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Thiebaut, MD</last_name>
      <phone>+3347676757563409</phone>
      <email>athiebautbertrand@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Thiebaut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, MD</last_name>
      <phone>+33240083994</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <state>Maine-et-Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Francois, MD</last_name>
      <phone>+332413544724475</phone>
      <email>syfrancois@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Francois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Val-de-Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Cordonnier, MD</last_name>
      <phone>+33149812057</phone>
      <email>catherine.cordonnier@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Cordonnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besnçon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Deconinck, MD, PhD</last_name>
      <phone>+33381668232</phone>
      <email>edeconinck@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Turlure, MD</last_name>
      <phone>+33555058039</phone>
      <email>pascal.turlure@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Turlure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Huynh, MD</last_name>
      <phone>+33531156354</phone>
      <email>huynh.anne@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, MD</last_name>
      <phone>+493419713132</phone>
      <email>dietger.niederwieser@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dietger Niederwieser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin Luther Universitat Halle Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Müller, MD</last_name>
      <phone>+493455577250</phone>
      <email>lutz.mueller@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Lutz Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaufmann, MD</last_name>
      <phone>+4971181015431</phone>
      <email>martin.kaufmann@rbk.de</email>
    </contact>
    <investigator>
      <last_name>Martin Kaufmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Bethge, MD</last_name>
      <phone>+4970712982711</phone>
      <email>wolfgang.bethge@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Remenyi, MD</last_name>
      <phone>+3614558218</phone>
      <email>premenyi@dpckorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Peter Remenyi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>+390113135230</phone>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Di Verona</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Tecchio, MD</last_name>
      <phone>+390458124443</phone>
      <email>cristina.tecchio@univr.it</email>
    </contact>
    <investigator>
      <last_name>Cristina Tecchio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Dell'Angelo</name>
      <address>
        <city>Zelarino</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Vespignani, MD</last_name>
      <phone>+390419657357</phone>
      <email>michele.vespignani@aulss3.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Michele Vespignani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Saccardi, MD</last_name>
      <phone>+390557947672</phone>
      <email>riccardo.saccardi@aouc.unifi.it</email>
    </contact>
    <investigator>
      <last_name>Riccardo Saccardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Chiusolo, MD</last_name>
      <phone>+393355267999</phone>
      <email>patrizia.chiusolo@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Patrizia Chiusolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Hyun Kim, MD</last_name>
      <phone>+82512402608</phone>
      <email>kshmoon@dau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sung Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Dae-gu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Rok Do, MD</last_name>
      <phone>+82532507719</phone>
      <email>dyr1160@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Young Rok Do, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canterbury Health Laboratories</name>
      <address>
        <city>Christchurch</city>
        <state>South Island</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Butler, MB, MD</last_name>
      <phone>+6433640392</phone>
      <email>andrew.butler@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Andrew Butler, MB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp z o o</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wieslaw Jedrzejczak, MD, PhD</last_name>
      <phone>+48225725959</phone>
      <email>wieslaw.jedrzejczak@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Wieslaw Jedrzejczak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne - PPDS</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Bieniaszewska, MD, PhD</last_name>
      <phone>+48583493070</phone>
      <email>mbienia@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Maria Bieniaszewska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Piu Koh, MBBS</last_name>
      <phone>+656321470</phone>
      <email>liang_piu_koh@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Liang Piu Koh, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aloysius Ho, MD</last_name>
      <phone>+6563214722</phone>
      <email>aloysius.ho.y.l@sgh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Aloysius Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Ferra Coll, PhD</last_name>
      <phone>+34934978987</phone>
      <email>cferra@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Christelle Ferra Coll, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Aranzazu Bermúdez Rodríguez, MD</last_name>
      <phone>+34942202520</phone>
      <email>maranzazu.bermudez@scsalud.es</email>
    </contact>
    <investigator>
      <last_name>María Aranzazu Bermúdez Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lourdes Vazquez Lopez, PhD</last_name>
      <phone>+34923291316</phone>
      <email>lvazlo@usal.es</email>
    </contact>
    <investigator>
      <last_name>Maria Lourdes Vazquez Lopez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.H. Regional Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Rojas Contreras, PhD</last_name>
      <phone>+34957012972</phone>
      <email>rrojashurs@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Rojas Contreras, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Jurado Chacón, PhD</last_name>
      <phone>+34958020379</phone>
      <email>manuel.jurado.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Jurado Chacón, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael De la Camara, MD</last_name>
      <phone>+34915202316</phone>
      <email>jrcamara@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Rafael De la Camara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Lopez Jimenez, PhD</last_name>
      <phone>+34913368362</phone>
      <email>jlopezj.hrc@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Lopez Jimenez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Duarte Palomino, PhD</last_name>
      <phone>+34911917809</phone>
      <email>rduarte.work@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Duarte Palomino, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Solano, PhD</last_name>
      <phone>+34963862625</phone>
      <email>carlos.solano@uv.es</email>
    </contact>
    <investigator>
      <last_name>Carlos Solano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Sanz Caballer, PhD</last_name>
      <phone>+34961245876</phone>
      <email>sanz_jai@gva.es</email>
    </contact>
    <investigator>
      <last_name>Jaime Sanz Caballer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Mueller, MD</last_name>
      <phone>+41442553712</phone>
      <email>nicolas.mueller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baskent University Medical Faculty Adana Practice and Research Center</name>
      <address>
        <city>Adana</city>
        <zip>1250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakan Ozdogu, MD</last_name>
      <phone>+00905322366797</phone>
      <email>hakanozdogu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hakan Ozdogu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ankara University</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunhan Gurman, MD</last_name>
      <phone>+903125957375</phone>
      <email>gurman@medicine.ankara.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Gunhan Gurman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>West Midlands</city>
        <state>Birmingham</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhuvan Kishore, MD</last_name>
      <phone>+441214243699</phone>
      <email>bhuvan.kishore@heartofengland.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Bhuvan Kishore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragana Milojkovic, MD</last_name>
      <phone>+442083835101</phone>
      <email>dragana.milojkovic@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Dragana Milojkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Peggs, MD</last_name>
      <phone>+442076796236</phone>
      <email>karl.peggs@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Karl Peggs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahuman Salim, MB, MRCPCH</last_name>
      <phone>+441517064639</phone>
      <email>rahuman.salim@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rahuman Salim, MB, MRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Bloor, BA, MB, PhD</last_name>
      <phone>+441614463869</phone>
      <email>adrian.bloor@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adrian Bloor, BA, MB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

